Thousands of people who took Elmiron for interstitial cystitis are now part of a major class action lawsuit because the drug caused permanent vision loss and eye damage that the manufacturer failed to warn them about. As of February 2026, there are 640 lawsuits pending in federal court in New Jersey, with victims receiving settlement checks ranging from $20,000 to $1,000,000 depending on the severity of their vision damage. The core issue is straightforward: Janssen Pharmaceuticals manufactured Elmiron without adequately disclosing that long-term use could cause maculopathy, a serious retinal condition that damages eyesight in ways that are mostly irreversible.
For people who took Elmiron as directed for interstitial cystitis—a chronic bladder condition affecting primarily women—the discovery that their medication was damaging their vision came as a shock. A typical case involves someone who took Elmiron for years to manage bladder pain, only to develop vision problems and learn from their eye doctor that Elmiron exposure had created toxins in their retina. The lawsuit exists because patients were never adequately warned about this risk before taking the medication.
Table of Contents
- What Is Elmiron and Why Does It Cause Vision Loss?
- The Failure to Warn and the Legal Claims
- How Many People Are Affected and What Has Happened So Far?
- Settlement Amounts and How They Are Determined
- Medical Documentation and Proving Vision Damage
- Steps to Join or File a Claim
- The Broader Context and Future Outlook
- Conclusion
What Is Elmiron and Why Does It Cause Vision Loss?
Elmiron (pentosan polysulfate sodium) is a medication approved by the FDA in 1996 specifically to treat interstitial cystitis, a painful bladder condition that causes chronic pelvic pain and urinary urgency. The drug works by helping protect the bladder lining, and for many patients, it provided relief from debilitating IC symptoms that interfere with daily life. However, clinical evidence accumulated over the decades showing that long-term Elmiron use causes a specific type of eye damage called maculopathy—damage to the macula, the part of the retina responsible for detailed central vision.
The mechanism is biochemical: when Elmiron is taken regularly over months and years, it creates toxic deposits in the retina. Unlike some medications that may cause temporary side effects that resolve once you stop taking the drug, Elmiron’s vision damage is described as “mostly irreversible.” This means that even after discontinuing the medication, the vision loss typically does not return. A patient who took Elmiron for five years and developed macular damage cannot simply stop the medication and regain their sight—the damage is permanent. This permanent nature of the injury is why the lawsuits have attracted so much attention and why settlement amounts have been substantial.
The Failure to Warn and the Legal Claims
The central legal claim in this case is that Janssen Pharmaceuticals knew or should have known about the vision risk associated with Elmiron but failed to adequately warn patients and doctors. FDA-approved medications come with warning labels that describe known side effects and risks, allowing patients to make informed decisions about whether the benefits of the drug outweigh the potential harms. The allegation is that Janssen’s labeling for Elmiron was inadequate—it either did not mention the maculopathy risk or buried the warning in language that failed to communicate the severity and permanence of the vision loss.
A crucial limitation in these cases is establishing when Janssen knew about the risk. The company’s defense typically hinges on claiming that the vision damage risk was not clearly established or commonly recognized in the medical community at the time the drug was being prescribed. However, accumulated case reports and clinical studies eventually made it clear that long-term Elmiron use was linked to retinal damage, leading to regulatory attention and ultimately to the lawsuits. The warning label was eventually updated, but this came after many patients had already sustained irreversible eye damage.
How Many People Are Affected and What Has Happened So Far?
The litigation has been consolidated into a federal multidistrict litigation (MDL) in the U.S. District Court of New Jersey before Judge Brian R. Martinotti. This consolidation allows hundreds of similar lawsuits to be managed together, with coordinated discovery and settlement negotiations.
As of February 2026, there are 640 lawsuits pending in this MDL. The caseload has actually declined from earlier peaks—there were 1,273 cases filed by March 2025, which dropped to 1,091 cases by April 2025, a reduction of 182 cases, likely due to settlements being finalized. What’s important to understand is that settlements have already been actively occurring in 2024 and into 2025, meaning victims are already receiving compensation. This is not a case where plaintiffs are still waiting for a decision or settlement—the litigation has progressed to the point where defendants are paying damages. These settlements are individual determinations based on the specifics of each case, primarily considering the extent of vision damage and its impact on the person’s life.
Settlement Amounts and How They Are Determined
The settlement range for Elmiron cases is between $20,000 and $1,000,000, a wide span that reflects the variable nature of the injuries. Someone who developed mild maculopathy that affects peripheral vision might receive $20,000 to $50,000, while someone who developed severe central vision loss that prevents them from driving or reading might receive $500,000 or more. The variation exists because vision damage from Elmiron differs significantly from person to person—some people develop significant symptoms while others have subtle changes detected mainly through eye examinations.
Determining factors for settlement amounts include the severity of vision damage as documented by ophthalmology records, the duration of Elmiron use, the baseline quality of vision before the drug (did you have perfect vision or pre-existing vision problems), and the impact on your life and work. Someone who was a truck driver and lost the ability to drive due to vision loss has a stronger damages claim than someone whose vision damage was subtle. There is a practical tradeoff here: accepting a settlement means giving up your right to pursue further claims, but it also provides compensation without the uncertainty and expense of continuing litigation.
Medical Documentation and Proving Vision Damage
To be part of this settlement, you must have documented evidence that you took Elmiron and that you developed maculopathy or related retinal damage. This typically requires medical records from your prescribing doctor showing the dates you took the medication and eye examination records from an ophthalmologist documenting the retinal damage. Self-reported vision problems are not sufficient—you need actual clinical evidence of maculopathy.
A significant limitation is that vision damage from Elmiron can be subtle in early stages. Some people develop it gradually without noticing significant symptoms until the damage is moderate. If you stopped taking Elmiron years ago and never had a comprehensive eye examination since then, you may not have the documentation needed to prove the connection to Elmiron in a settlement claim. Additionally, people with other conditions that affect vision—such as age-related macular degeneration, diabetic retinopathy, or high myopia—may face challenges in proving that their vision loss was specifically caused by Elmiron rather than their other condition.
Steps to Join or File a Claim
If you took Elmiron and have experienced vision problems, your first step should be to gather your medical records—pharmacy records showing when you filled Elmiron prescriptions and eye examination reports documenting any retinal damage. You can then contact an attorney who handles Elmiron lawsuits to discuss whether you have a viable claim.
Many personal injury attorneys work on contingency, meaning you don’t pay attorney’s fees unless you win or settle your case. It’s important to act within applicable statutes of limitations, which vary by state but typically range from 2 to 6 years from when you discovered the injury. If you stopped taking Elmiron five years ago and have only now noticed vision problems or been diagnosed with maculopathy, you likely still have time to file, but it’s important to consult with an attorney promptly.
The Broader Context and Future Outlook
The Elmiron litigation is part of a larger pattern of pharmaceutical companies discovering—sometimes too late—that widely-used medications carry serious risks that were not adequately disclosed. The case highlights the importance of long-term safety monitoring and transparent communication between drug manufacturers, regulators, and patients.
The fact that the settlement range goes as high as $1 million reflects how serious vision loss is as an injury: people depend on sight for independence, employment, and quality of life. Looking forward, this case may prompt more rigorous long-term safety studies for drugs used chronically, particularly those prescribed to vulnerable populations like IC patients, who are predominantly women and often desperate for any treatment that provides relief. The settlements being paid now represent compensation for past harm, but they also serve as a mechanism for holding manufacturers accountable when they fail to adequately warn the public about known risks.
Conclusion
The Elmiron vision loss class action represents a significant settlement with over 640 pending lawsuits as of February 2026 and settlements already being paid out in amounts ranging from $20,000 to $1,000,000. The core issue is that Janssen Pharmaceuticals failed to adequately warn patients that long-term Elmiron use for interstitial cystitis could cause permanent retinal damage and vision loss. The vision damage from Elmiron is mostly irreversible, making this a serious injury that justifies substantial compensation.
If you took Elmiron and have developed vision problems or been diagnosed with maculopathy, you may be eligible for compensation. The key steps are to gather your medical records documenting both your Elmiron use and your eye damage, consult with an attorney experienced in Elmiron cases, and act within the applicable statute of limitations. Thousands of other victims have already received settlements, and the litigation continues to move forward with new cases being resolved regularly.